Short-term Working Memory and Executive Training

Psychotic Disorders Clinical Trial

— STExFx  

Official title:

Short-Term Executive Functioning Training

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02168166
• Other study ID #: GPSYC-651-14
• Status: Completed
• Phase: N/A
• First received: June 16, 2014
• Last updated: April 2, 2018
• Start date: May 2014
• Est. completion date: June 2017

Study information

• Verified date: April 2018
• Source: Queen's University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Cognitive remediation (CR) therapies refer to a number of recent developments to use behavioural strategies to improve neurocognitive abilities and improve everyday functioning in mental disorders such as schizophrenia, bipolar disorder, and depression. In this study, we aim to examine whether we can observe CR effects on measures of neuroplasticity, cognition, and functioning when using a rigorous control comparison group. We hypothesize that the active group will exhibit improvements in executive functioning composite scores, improved EEG theta-gamma frequency modulation, and increased EEG alpha power compared to the placebo group.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: June 2017
• Est. primary completion date: June 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• diagnosis of a chronic mental disorder (defined herein as bipolar disorder, major depressive disorder, or a schizophrenia-spectrum disorder)

• between the ages of 18 and 65

• speak and read fluent English

• able to use a computer

Exclusion Criteria:

• active substance abuse or dependence diagnosis

• sensory or motor issues that would preclude completion of study procedures

• enrollment in a cognitive remediation program or use of cognitive training programs (e.g. lumosity.com) within the past 6 months

Related Conditions & MeSH terms

• Mental Disorders
• Psychotic Disorders

Intervention

Behavioral:
• Executive Function Training

• Placebo
Placebo version of executive function training

Locations

Country	Name	City	State
Canada	Queen's University	Kingston	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
Queen's University

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline executive functioning composite score at post-treatment assessment	Composite score based on four tests of cognition	Pre-training assessment (Week 1) and post-training assessment (Week 4)
Secondary	Change from baseline EEG theta-gamma frequency modulation at post-treatment assessment	Predicted to improve in active CR (cognitive remediation) condition compared to placebo CR	Pre-training assessment (Week 1) and post-training assessment (Week 4)
Secondary	Change from baseline EEG alpha power at post-treatment assessment	Predicted to increase in active CR (cognitive remediation) condition compared to placebo CR	Pre-training assessment (Week 1) and post-training assessment (Week 4)